デフォルト表紙
市場調査レポート
商品コード
1014114

世界の代謝障害治療薬市場規模調査:投与ルート別、疾患別、治療タイプ別、地域別予測(2021~2027年)

Global Metabolic Disorder Therapeutics Market Size study, by Route of Administration, by Disease, by Therapy Type, and Regional Forecasts 2021-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
世界の代謝障害治療薬市場規模調査:投与ルート別、疾患別、治療タイプ別、地域別予測(2021~2027年)
出版日: 2021年06月11日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の代謝障害治療薬の市場規模は2020年に約601億6千万米ドルとなりました。

同市場は、2021年から2027年の予測期間にわたって7.30%以上の健全な成長率で拡大すると予測されています。

代謝障害は、体内の異常な化学反応が消化された食物からエネルギーを作るプロセスを混乱させるときに発生します。代謝障害の治療に対する意識の高まりと新しい調査および技術の進歩により、代謝障害治療薬市場が推進されています。さまざまな代謝障害、特に肥満や糖尿病の発生率の上昇も、代謝障害治療薬市場を牽引しています。

世界保健機関によると、2019年に世界で推定150万人が糖尿病により死亡したと報告されました。2012年にはさらに220万人に増加しています。2019年、国際糖尿病連盟は約4億6,300万人の成人(20~79歳)が糖尿病を患っており。これが2045年には7億人に達すると予測しています。2型糖尿病患者の割合はほとんどの国で増加しており、糖尿病患者の79%が低中所得国に住んでいます。世界中で110万人以上の子供と青年が1型糖尿病を患っています。希少疾患に対するいくつかの治療法が高価であること、および明確な規制政策の欠如は、市場の成長を抑制するとみられています。しかし、COVID-19パンデミック後の肥満の有害な影響と良好な代謝の重要性に対する意識の高まりは、その後の10年間の代謝障害治療薬市場の機会になると見込まれています。

当レポートでは、世界の代謝障害治療薬市場について調査し、市場の概要とともに、投与ルート別、疾患別、治療タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の代謝障害治療薬市場の定義と範囲

第3章 世界の代謝障害治療薬市場力学

  • 代謝障害治療薬市場の影響分析(2019~2027年)

第4章 世界の代謝障害治療薬市場業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論

第5章 世界の代謝障害治療薬市場、疾患別

  • 市場スナップショット
  • 世界の代謝障害治療薬市場、疾患別:パフォーマンス-潜在的な分析
  • 世界の代謝障害治療薬市場の見積と予測、疾患別:2018~2027年(10億米ドル)
  • 代謝障害治療薬市場、サブセグメント分析
    • リソソーム蓄積症
    • 糖尿病
    • 肥満
    • 先天性代謝異常症
    • 高コレステロール血症

第6章 世界の代謝障害治療薬市場、投与ルート別

  • 市場スナップショット
  • 世界の代謝障害治療薬市場、投与ルート別:パフォーマンス-潜在的な分析
  • 世界の代謝障害治療薬市場の見積と予測、投与ルート別:2018~2027年(10億米ドル)
  • 代謝障害治療薬市場、サブセグメント分析
    • 経口投与
    • 非経口投与
    • その他

第7章 世界の代謝障害治療薬市場、治療タイプ別

  • 市場スナップショット
  • 世界の代謝障害治療薬市場、治療タイプ別:パフォーマンス-潜在的な分析
  • 世界の代謝障害治療薬市場の見積と予測、治療タイプ別:2018~2027年(10億米ドル)
  • 代謝障害治療薬市場、サブセグメント分析
    • 酵素補充療法
    • 細胞移植
    • 低分子治療
    • 基質減少療法
    • 遺伝子治療
    • 薬物療法

第8章 世界の代謝障害治療薬市場、地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第9章 競合情報

  • トップ市場戦略
  • 企業プロファイル
  • ノボノルディスク
    • Eli Lilly and Company
    • Shire Plc
    • Sanofi
    • Merck KGaA
    • AstraZeneca
    • AbbVie Inc.,
    • Actelion Pharmaceuticals Ltd
    • Amgen Inc.,
    • Biocon

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Metabolic Disorder Therapeutics Market, report scope
  • TABLE 2. Global Metabolic Disorder Therapeutics Market estimates & forecasts by region 2018-2027 (USD Billion)
  • TABLE 3. Global Metabolic Disorder Therapeutics Market estimates & forecasts by Disease 2018-2027 (USD Billion)
  • TABLE 4. Global Metabolic Disorder Therapeutics Market estimates & forecasts by Route of Administration 2018-2027 (USD Billion)
  • TABLE 5. Global Metabolic Disorder Therapeutics Market estimates & forecasts by Therapy Type 2018-2027 (USD Billion)
  • TABLE 6. Global Metabolic Disorder Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 7. Global Metabolic Disorder Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Metabolic Disorder Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Metabolic Disorder Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Metabolic Disorder Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Metabolic Disorder Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Metabolic Disorder Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Metabolic Disorder Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. Global Metabolic Disorder Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. Global Metabolic Disorder Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 16. U.S. Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 17. U.S. Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 18. U.S. Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 19. Canada Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 20. Canada Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 21. Canada Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 22. UK Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 23. UK Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 24. UK Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 25. Germany Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 26. Germany Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 27. Germany Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 28. RoE Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 29. RoE Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 30. RoE Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 31. China Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 32. China Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 33. China Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 34. India Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 35. India Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 36. India Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 37. Japan Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 38. Japan Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 39. Japan Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 40. RoAPAC Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 41. RoAPAC Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 42. RoAPAC Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 43. Brazil Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 44. Brazil Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 45. Brazil Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 46. Mexico Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 47. Mexico Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 48. Mexico Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 49. RoLA Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 50. RoLA Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 51. RoLA Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 52. Row Metabolic Disorder Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 53. Row Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 54. Row Metabolic Disorder Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 55. List of secondary sources, used in the study of global Metabolic Disorder Therapeutics Market
  • TABLE 56. List of primary sources, used in the study of global Metabolic Disorder Therapeutics Market
  • TABLE 57. Years considered for the study
  • TABLE 58. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Metabolic Disorder Therapeutics Market, research methodology
  • FIG 2. Global Metabolic Disorder Therapeutics Market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Metabolic Disorder Therapeutics Market, key trends 2020
  • FIG 5. Global Metabolic Disorder Therapeutics Market, growth prospects 2021-2027
  • FIG 6. Global Metabolic Disorder Therapeutics Market, porters 5 force model
  • FIG 7. Global Metabolic Disorder Therapeutics Market, pest analysis
  • FIG 8. Global Metabolic Disorder Therapeutics Market, value chain analysis
  • FIG 9. Global Metabolic Disorder Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Metabolic Disorder Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Metabolic Disorder Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Metabolic Disorder Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Metabolic Disorder Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Metabolic Disorder Therapeutics Market, regional snapshot 2018 & 2027
  • FIG 15. North America Metabolic Disorder Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 16. Europe Metabolic Disorder Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 17. Asia pacific Metabolic Disorder Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 18. Latin America Metabolic Disorder Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 19. Global Metabolic Disorder Therapeutics Market, company market share analysis (2020)
目次

Global Metabolic Disorder Therapeutics Market is valued approximately USD 60.16 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.30% over the forecast period 2021-2027. Metabolic disorder occurs when abnormal chemical reactions in the body disrupt the process of making energy from the digested food. The rising awareness for the treatment of metabolic disorders and the new research and technological advancements are propelling the Metabolic Disorder Therapeutics market. The rising incidences of various metabolic disorders, especially obesity and diabetes, are also driving the Metabolic Disorder Therapeutics market. According to World Health Organization, an estimated 1.5 million deaths were directly caused by diabetes globally in 2019. Another 2.2 million deaths were attributable to high blood glucose in 2012. In 2019, International Diabetes Federation reports that approximately 463 million adults (20-79 years) were living with diabetes which will rise to 700 million in 2045. Proportion of people with type 2 diabetes is increasing in most countries, with 79% of adults with diabetes living in low- and middle-income countries. More than 1.1 million children and adolescents are living with type 1 diabetes worldwide. The expensive nature of some therapies for rare diseases as well as lack of unequivocal regulatory policies may act as a restraint for its growth. However, increasing awareness for harmful effects of obesity and importance of good metabolism after COVID-19 pandemic acts as an opportunity for Metabolic Disorder Therapeutics Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Metabolic Disorder Therapeutics Market. Due to higher expenditure on healthcare as well as higher per capita income, North America has emerged as the significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit the highest growth rate for the forecast period 2021-2027 owing to the rising disposable income and growing incidences of diabetes and obesity along with other metabolic disorders in the region.

Major market player included in this report are:

Novo Nordisk

Eli Lilly and Company

Shire Plc

Sanofi

Merck KGaA

AstraZeneca

AbbVie Inc.,

Actelion Pharmaceuticals Ltd

Amgen Inc.,

Biocon

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease:

Lysosomal Storage Diseases

Diabetes

Obesity

Inherited Metabolic Disorders

Hypercholesterolemia

By Route of Administration:

Oral Administration

Parenteral Administration

Other route of administration

By Therapy Type:

Enzyme Replacement Therapy

Cellular Transplantation

Small Molecule-Based Therapy

Substrate Reduction Therapy

Gene Therapy

Drug Therapy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027

Target Audience of the Global Metabolic Disorder Therapeutics Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1.Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Metabolic Disorder Therapeutics Market, by Disease, 2019-2027 (USD Billion)
    • 1.2.2. Metabolic Disorder Therapeutics Market, by Route of Administration, 2019-2027 (USD Billion)
    • 1.2.3. Metabolic Disorder Therapeutics Market, by Therapy Type, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Metabolic Disorder Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Metabolic Disorder Therapeutics Market Dynamics

  • 3.1. Metabolic Disorder Therapeutics Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidences of diabetes and obesity
      • 3.1.1.2. Research and development in the field therapy
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of treatment of rare diseases
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increased expenditure from government and international bodies

Chapter 4. Global Metabolic Disorder Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Metabolic Disorder Therapeutics Market, by Disease

  • 5.1. Market Snapshot
  • 5.2. Global Metabolic Disorder Therapeutics Market by Disease, Performance - Potential Analysis
  • 5.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Disease 2018-2027 (USD Billion)
  • 5.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Lysosomal Storage Diseases
    • 5.4.2. Diabetes
    • 5.4.3. Obesity
    • 5.4.4. Inherited Metabolic Disorders
    • 5.4.5. Hypercholesterolemia

Chapter 6. Global Metabolic Disorder Therapeutics Market, by Route of Administration

  • 6.1. Market Snapshot
  • 6.2. Global Metabolic Disorder Therapeutics Market by Route of Administration, Performance - Potential Analysis
  • 6.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Route of Administration 2018-2027 (USD Billion)
  • 6.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Oral Administration
    • 6.4.2. Parenteral Administration
    • 6.4.3. Other route of administration

Chapter 7. Global Metabolic Disorder Therapeutics Market, by Therapy Type

  • 7.1. Market Snapshot
  • 7.2. Global Metabolic Disorder Therapeutics Market by Therapy Type, Performance - Potential Analysis
  • 7.3. Global Metabolic Disorder Therapeutics Market Estimates & Forecasts by Therapy Type 2018-2027 (USD Billion)
  • 7.4. Metabolic Disorder Therapeutics Market, Sub Segment Analysis
    • 7.4.1. Enzyme Replacement Therapy
    • 7.4.2. Cellular Transplantation
    • 7.4.3. Small Molecule-Based Therapy
    • 7.4.4. Substrate Reduction Therapy
    • 7.4.5. Gene Therapy
    • 7.4.6. Drug Therapy

Chapter 8. Global Metabolic Disorder Therapeutics Market, Regional Analysis

  • 8.1. Metabolic Disorder Therapeutics Market, Regional Market Snapshot
  • 8.2. North America Metabolic Disorder Therapeutics Market
    • 8.2.1. U.S. Metabolic Disorder Therapeutics Market
      • 8.2.1.1. Disease breakdown estimates & forecasts, 2018-2027
      • 8.2.1.2. Route of Administration breakdown estimates & forecasts, 2018-2027
      • 8.2.1.3. Therapy Type breakdown estimates & forecasts, 2018-2027
    • 8.2.2. Canada Metabolic Disorder Therapeutics Market
  • 8.3. Europe Metabolic Disorder Therapeutics Market Snapshot
    • 8.3.1. U.K. Metabolic Disorder Therapeutics Market
    • 8.3.2. Germany Metabolic Disorder Therapeutics Market
    • 8.3.3. France Metabolic Disorder Therapeutics Market
    • 8.3.4. Spain Metabolic Disorder Therapeutics Market
    • 8.3.5. Italy Metabolic Disorder Therapeutics Market
    • 8.3.6. Rest of Europe Metabolic Disorder Therapeutics Market
  • 8.4. Asia-Pacific Metabolic Disorder Therapeutics Market Snapshot
    • 8.4.1. China Metabolic Disorder Therapeutics Market
    • 8.4.2. India Metabolic Disorder Therapeutics Market
    • 8.4.3. Japan Metabolic Disorder Therapeutics Market
    • 8.4.4. Australia Metabolic Disorder Therapeutics Market
    • 8.4.5. South Korea Metabolic Disorder Therapeutics Market
    • 8.4.6. Rest of Asia Pacific Metabolic Disorder Therapeutics Market
  • 8.5. Latin America Metabolic Disorder Therapeutics Market Snapshot
    • 8.5.1. Brazil Metabolic Disorder Therapeutics Market
    • 8.5.2. Mexico Metabolic Disorder Therapeutics Market
  • 8.6. Rest of The World Metabolic Disorder Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
  • 9.3. Novo Nordisk
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Eli Lilly and Company
    • 9.3.3. Shire Plc
    • 9.3.4. Sanofi
    • 9.3.5. Merck KGaA
    • 9.3.6. AstraZeneca
    • 9.3.7. AbbVie Inc.,
    • 9.3.8. Actelion Pharmaceuticals Ltd
    • 9.3.9. Amgen Inc.,
    • 9.3.10. Biocon

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption